Last reviewed · How we verify
human chorionic gonadotropin
Human chorionic gonadotropin (hCG) is a glycoprotein hormone that binds to luteinizing hormone receptors to stimulate gonadal steroid production and gametogenesis.
Human chorionic gonadotropin (hCG) is a glycoprotein hormone that binds to luteinizing hormone receptors to stimulate gonadal steroid production and gametogenesis. Used for Female infertility (ovulation induction, assisted reproductive technology), Male hypogonadism and infertility (testosterone replacement, spermatogenesis stimulation), Pregnancy support (luteal phase support).
At a glance
| Generic name | human chorionic gonadotropin |
|---|---|
| Also known as | hCG, Choriomon, Human Chorionic Gonadotropin(hCG), Pregnyl, NV Organon, Oss, The Netherlands, Chorex |
| Sponsor | Martin Blomberg Jensen |
| Drug class | Gonadotropin; LH analog |
| Target | Luteinizing hormone receptor (LHCGR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Endocrinology |
| Phase | FDA-approved |
Mechanism of action
hCG mimics the action of luteinizing hormone (LH) by activating LH receptors on Leydig cells in males and theca cells in females, thereby promoting testosterone and estrogen/progesterone synthesis respectively. In males, it stimulates spermatogenesis and testosterone production; in females, it supports corpus luteum function and progesterone secretion during the luteal phase and early pregnancy.
Approved indications
- Female infertility (ovulation induction, assisted reproductive technology)
- Male hypogonadism and infertility (testosterone replacement, spermatogenesis stimulation)
- Pregnancy support (luteal phase support)
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/bloating
- Nausea
Key clinical trials
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- INTEnsity of ovariaN Stimulation and Embryo Quality (PHASE4)
- Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study
- Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm (PHASE2)
- Assessment of the Feasibility of Frozen Embryo Transfers in a Natural Cycle Among Obese Compared to Non-Obese Patients
- PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis (PHASE1)
- FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles (NA)
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- human chorionic gonadotropin CI brief — competitive landscape report
- human chorionic gonadotropin updates RSS · CI watch RSS
- Martin Blomberg Jensen portfolio CI